FindTrial
Sign In

To compare CRP albumin ratio, neutrophil lymphocyte ratio and platelet lymphocyte ratio between normal and non-infectious uveitis patients which help us in prognostication and treatment of the disease.

Assessing implications for prognosis and management of non-infectious uveitis based on novel inflammatory serum biomarkers. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/09/074457
Enrollment
202
Registered
2024-09-26
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H22- Disorders of iris and ciliary bodyin diseases classified elsewhere

Interventions

Intervention1: NIL: NIL

Sponsors

Sankara eye hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients presenting with first attack of active uveitis (anterior, intermediate, posterior and panuveitis)

Exclusion criteria

Exclusion criteria: Patients with infectious uveitis. Intraocular surgery in the last 3 months. Having a history of ocular trauma or chronic medication use. Acute or chronic systemic infective disorders, cancer. Acute coronary syndrome, cerebral disease, trauma or anemia. Those using anti-inflammatory or immunosuppressive drugs. Pregnant women.

Design outcomes

Primary

MeasureTime frame
To assess the levels of CRP, CRP - albumin ratio(CAR), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and systemic immune-inflammation index (SII) in patients with active non- infectious uveitis and comparison with normal controls. Timepoint: At baseline—

Secondary

MeasureTime frame
To study the correlation between different novel biomarkers and its significance.Timepoint: At baseline—

Countries

India

Contacts

Public ContactDr Neethu Narasimhaiah

Sankara eye hospital

neet.capricorn@gmail.com7022943710

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026